NCT03056352

Brief Summary

Post-traumatic headache is common. We are determining short and longer-term outcomes among patients treated for post-traumatic headache with IV metoclopramide.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
21

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started Mar 2017

Shorter than P25 for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 14, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

February 17, 2017

Completed
12 days until next milestone

Study Start

First participant enrolled

March 1, 2017

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 20, 2017

Completed
26 days until next milestone

Study Completion

Last participant's last visit for all outcomes

August 15, 2017

Completed
12 months until next milestone

Results Posted

Study results publicly available

July 31, 2018

Completed
Last Updated

July 31, 2018

Status Verified

July 1, 2018

Enrollment Period

5 months

First QC Date

February 14, 2017

Results QC Date

May 8, 2018

Last Update Submit

July 2, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of Participants With Sustained Headache Relief

    Sustained headache relief is defined as achieving a headache level of "mild" or "none" within two hours and maintaining a level of "mild" or "none" for 48 hours. Patient self-evaluated pain level is solicited every half hour for two hours in the Emergency Department and then by telephone 48 hours after medication administration.

    2 hours thru 48 hours after treatment

Secondary Outcomes (2)

  • Post Concussion Symptoms Assessed by Post-concussive Symptom Scale

    7 days

  • Number of Participants Satisfied With Medication; Assessed by Self-evaluation

    48 hours after treatment

Study Arms (1)

Metoclopramide

EXPERIMENTAL

Metoclopramide 20mg + diphenhydramine 25mg administered intravenously over 15 minutes

Drug: MetoclopramideDrug: Diphenhydramine

Interventions

Intravenous medication drip

Also known as: Reglan
Metoclopramide

Intravenous medication drip

Also known as: Benadryl
Metoclopramide

Eligibility Criteria

Age18 Years+
Sexall(Gender-based eligibility)
Gender Eligibility DetailsPer patient
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Traumatic injury to the head has occurred
  • Headache has developed within 7 days of injury to the head
  • Headache is not better accounted for by another diagnosis (eg, previous history of migraine or tension-type headache)
  • The headache must be rated as moderate or severe in intensity at the time of initial evaluation.
  • The plan of the attending emergency physician must include treatment with parenteral metoclopramide.

You may not qualify if:

  • Patients will be excluded if more than ten days have elapsed since the head trauma, if the headache has already been treated with an anti-dopaminergic medication, or for medication contra-indications including pheochromocytoma, seizure disorder, Parkinson's disease, use of monoamine oxidase inhibitors, and use of anti-rejection transplant medications. Patients will not be excluded for pregnancy or breast-feeding.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Montefiore Medical Center

The Bronx, New York, 10467, United States

Location

MeSH Terms

Conditions

Post-Traumatic Headache

Interventions

MetoclopramideDiphenhydramine

Condition Hierarchy (Ancestors)

Headache Disorders, SecondaryHeadache DisordersBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

BenzamidesAmidesOrganic Chemicalspara-AminobenzoatesAminobenzoatesBenzoatesAcids, CarbocyclicCarboxylic AcidsChlorobenzoatesHydroxybenzoate EthersHydroxybenzoatesHydroxy AcidsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsPhenyl EthersPhenolsEthylaminesAminesBenzhydryl Compounds

Results Point of Contact

Title
Benjamin W. Friedman, MD
Organization
Montefiore Health

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

February 14, 2017

First Posted

February 17, 2017

Study Start

March 1, 2017

Primary Completion

July 20, 2017

Study Completion

August 15, 2017

Last Updated

July 31, 2018

Results First Posted

July 31, 2018

Record last verified: 2018-07

Data Sharing

IPD Sharing
Will not share

Locations